Showing 591-600 of 1846 results for "".
DermWireTV: Medicare Cuts; Revision, Alastin, Obagi Acquisitions; CSF Hits Nashville
https://practicaldermatology.com/topics/practice-management/dermwiretv-medicare-cuts-revision-alastin-obagi-acquisitions-csf-hits-nashville/20033/Congress is working to avert a potential pay cut for physicians who treat Medicare patients, and a bipartisan solution has been introduced. Cuts loom as the AMA has released data showing that Medicare claims data exclusive to physician services fell an estimated $13.9 billion or 14 percent below expSunscreen Ratings, Restylane Lyft for Hands, NPF, SCF News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-ratings-restylane-lyft-for-hands-npf-scf-news/18305/Both Consumer Reports and the Environmental Working Group have issued sunscreen rankings, and while some products shine, many products may underperform. FDA issued warnings to several companies illegally marketing dietary supplements that make unproven drug claims about protecting consumers from sunHumphries to Valeant, Restylane Line Expands, 2016 Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-humphries-to-valeant-restylane-line-expands-2016-highlights/18709/The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needsSafe, Effective Treatments for Hair Loss
https://practicaldermatology.com/topics/hair-nails/safe-effective-treatments-for-hair-loss/26951/Safe, Effective Treatments for Hair LossDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiProviding the Best Outcomes with Dermal Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/glaser/18972/What can we look forward to in the way of fillers in the year ahead? According to Dee Anna Glaser, MD, there may be several new tools in your tool chest, but in the end, it's how they're utilized that's most important. Dr. Glaser, Vice Chairman, Dept. of Dermatology, St. Louis University School ofHelping Patients Look Like Their Best Personal Self
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/shamban/18973/Has someone come into your office asking to look radically different? That's a big red flag warning for Ava Shamban, MD, owner and director of two dermatological practices in Santa Monica and Beverly Hills, Calif., frequent TV commentator, and author of the book, “Heal Your Skin: The Breakthrough Pl- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe